Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SMART CAR-T Claudin 18.2
- Development stage
- Unknown
- Lead developer
- Gracell Biotechnologies
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
SMART CAR-T Claudin 18.2 (GC502) is an autologous chimeric antigen receptor T-cell (CAR-T) therapy developed by Gracell Biopharma (now a subsidiary of AstraZeneca) using its proprietary SMART CAR-T (Self-activating Multi-functional Anti-tumor Resistance T-cell) platform. This therapy is engineered to target Claudin 18.2 (CLDN18.2), a tight junction protein that is highly expressed in various solid tumors, including gastric, gastroesophageal junction, and pancreatic cancers, while having limited expression in normal tissues. The SMART CAR-T platform is specifically designed to overcome the immunosuppressive tumor microenvironment (TME) and enhance the persistence and expansion of CAR-T cells in solid tumors, which have historically been challenging for cell therapies. GC502 is currently being evaluated in investigator-initiated clinical trials (IIT) to assess its safety and preliminary efficacy in patients with CLDN18.2-positive advanced solid tumors.
- Other names
- SMART CAR-T Claudin18.2GC502GC-502GC 502
02
Targets
Claudin 18.2
Beyond the preview
Go deeper on SMART CAR-T Claudin 18.2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SMART CAR-T Claudin 18.2.